Spots Global Cancer Trial Database for keytruda®
Every month we try and update this database with for keytruda® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer | NCT06125197 | Lung Cancer | TILT-123 KEYTRUDA® | 18 Years - | TILT Biotherapeutics Ltd. | |
| Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | NCT06249048 | Advanced Solid ... | STX-001 Keytruda® | 18 Years - | Strand Therapeutics Inc. | |
| Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | NCT06320353 | Skin Melanoma | RPH-075 Keytruda® | 18 Years - | R-Pharm | |
| Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | NCT06307093 | Skin Melanoma Squamous Non-sm... Head and Neck S... | RPH-075 Keytruda® | 18 Years - | R-Pharm | |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | NCT03978689 | Head and Neck C... HPV Positive Or... HPV-Related Car... | CUE-101 KEYTRUDA® | 18 Years - | Cue Biopharma | |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | NCT03978689 | Head and Neck C... HPV Positive Or... HPV-Related Car... | CUE-101 KEYTRUDA® | 18 Years - | Cue Biopharma | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | NCT03138889 | Non-Small Cell ... | NKTR-214 Pembrolizumab NKTR-214 NKTR-214 Cisplatin Carboplatin Nab paclitaxel Paclitaxel Pemetrexed Atezolizumab | 18 Years - | Nektar Therapeutics | |
| Study of SRF617 in Patients With Advanced Solid Tumors | NCT04336098 | Advanced Solid ... | SRF617 Gemcitabine Albumin-Bound P... Pembrolizumab | 18 Years - | Surface Oncology | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] | NCT06137378 | Squamous Cell C... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngectomy; S... Laryngeal Cance... Laryngeal Neopl... | KEYTRUDA® | 18 Years - 70 Years | University of Leipzig | |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03082534 | HNSCC Lip SCC Oral Cavity Can... Oropharynx Canc... Larynx Cancer Hypopharynx Can... Nasopharynx Can... Sinonasal Carci... Cutaneous Squam... Head and Neck N... Head and Neck C... Head and Neck S... | Pembrolizumab, ... | 18 Years - | University of California, San Diego | |
| The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | NCT03444376 | Cervical Cancer | GX-188E KEYTRUDA® | 18 Years - | Genexine, Inc. | |
| Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | NCT06307093 | Skin Melanoma Squamous Non-sm... Head and Neck S... | RPH-075 Keytruda® | 18 Years - | R-Pharm | |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | NCT03138889 | Non-Small Cell ... | NKTR-214 Pembrolizumab NKTR-214 NKTR-214 Cisplatin Carboplatin Nab paclitaxel Paclitaxel Pemetrexed Atezolizumab | 18 Years - | Nektar Therapeutics | |
| Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | NCT04526691 | Advanced or Met... | Datopotamab der... KEYTRUDA® Carboplatin Cisplatin | 18 Years - | Daiichi Sankyo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
